Loading...

Intercept Pharmaceuticals

DB:I4P
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
I4P
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • Intercept Pharmaceuticals has significant price volatility in the past 3 months.
I4P Share Price and Events
7 Day Returns
-23%
DB:I4P
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
39.1%
DB:I4P
-7.9%
DE Biotechs
-7.2%
DE Market
I4P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Intercept Pharmaceuticals (I4P) -23% -16.7% -15% 39.1% -36.8% -58.3%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • I4P outperformed the Biotechs industry which returned -7.9% over the past year.
  • I4P outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
I4P
Industry
5yr Volatility vs Market
Related Companies

I4P Value

 Is Intercept Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Intercept Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Intercept Pharmaceuticals.

DB:I4P Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 20 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:I4P
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (14.03%))
1.414
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.41
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.414 * 5.96%)
8.65%

Discounted Cash Flow Calculation for DB:I4P using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Intercept Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:I4P DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.65%)
2019 -253.40 Analyst x6 -233.22
2020 -290.34 Analyst x5 -245.94
2021 -181.81 Analyst x3 -141.74
2022 400.55 Analyst x2 287.40
2023 319.27 Analyst x3 210.83
2024 268.98 Est @ -15.75% 163.48
2025 239.51 Est @ -10.96% 133.97
2026 221.30 Est @ -7.6% 113.93
2027 209.68 Est @ -5.25% 99.35
2028 202.11 Est @ -3.61% 88.14
Present value of next 10 years cash flows $476.21
DB:I4P DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $202.11 × (1 + 0.23%) ÷ (8.65% – 0.23%)
$2,404.35
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,404.35 ÷ (1 + 8.65%)10
$1,048.51
DB:I4P Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $476.21 + $1,048.51
$1,524.72
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,524.72 / 29.69
$51.35
DB:I4P Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:I4P represents 0.92349x of NasdaqGS:ICPT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.92349x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 51.35 x 0.92349
€47.42
Value per share (EUR) From above. €47.42
Current discount Discount to share price of €82.32
= -1 x (€82.32 - €47.42) / €47.42
-73.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Intercept Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intercept Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intercept Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:I4P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-10.86
NasdaqGS:ICPT Share Price ** NasdaqGS (2019-04-17) in USD $89.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intercept Pharmaceuticals.

DB:I4P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ICPT Share Price ÷ EPS (both in USD)

= 89.14 ÷ -10.86

-8.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intercept Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Intercept Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Intercept Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:I4P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 20 Analysts
48.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Intercept Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intercept Pharmaceuticals's assets?
Raw Data
DB:I4P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.64
NasdaqGS:ICPT Share Price * NasdaqGS (2019-04-17) in USD $89.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:I4P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ICPT Share Price ÷ Book Value per Share (both in USD)

= 89.14 ÷ 0.64

138.36x

* Primary Listing of Intercept Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intercept Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Intercept Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

I4P Future Performance

 How is Intercept Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 20 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intercept Pharmaceuticals expected to grow at an attractive rate?
  • Intercept Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Intercept Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Intercept Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:I4P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:I4P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 20 Analysts 48.4%
DB:I4P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 20 Analysts 34.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:I4P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:I4P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,409 564 675 6
2022-12-31 941 159 174 8
2021-12-31 505 -5 -196 10
2020-12-31 330 -171 -295 19
2019-12-31 237 -208 -295 20
DB:I4P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 180 -241 -309
2018-09-30 164 -264 -333
2018-06-30 159 -269 -341
2018-03-31 146 -277 -352
2017-12-31 131 -265 -360
2017-09-30 107 -278 -369
2017-06-30 71 -334 -385
2017-03-31 46 -350 -376
2016-12-31 25 -342 -413
2016-09-30 12 -319 -381
2016-06-30 7 -240 -343
2016-03-31 2 -203 -314

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intercept Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Intercept Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:I4P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below

All data from Intercept Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I4P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 19.87 26.24 11.15 5.00
2022-12-31 10.71 16.81 3.63 6.00
2021-12-31 -3.89 5.43 -9.97 11.00
2020-12-31 -8.01 -2.10 -13.71 15.00
2019-12-31 -9.78 -7.60 -10.92 17.00
DB:I4P Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -10.86
2018-09-30 -12.17
2018-06-30 -13.00
2018-03-31 -14.00
2017-12-31 -14.38
2017-09-30 -14.78
2017-06-30 -15.49
2017-03-31 -15.18
2016-12-31 -16.74
2016-09-30 -15.52
2016-06-30 -14.05
2016-03-31 -12.92

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intercept Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Intercept Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intercept Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

I4P Past Performance

  How has Intercept Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intercept Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intercept Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intercept Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intercept Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intercept Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intercept Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I4P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 179.80 -309.24 255.47 207.30
2018-09-30 164.21 -332.51 264.94 200.23
2018-06-30 158.56 -340.66 269.48 198.26
2018-03-31 145.87 -352.03 271.18 195.04
2017-12-31 130.96 -360.37 269.80 190.20
2017-09-30 107.08 -369.14 268.48 185.60
2017-06-30 70.92 -385.35 260.92 175.04
2017-03-31 45.55 -376.09 238.81 165.75
2016-12-31 24.95 -412.83 228.60 153.89
2016-09-30 11.59 -381.04 209.87 131.24
2016-06-30 6.86 -343.12 180.81 123.32
2016-03-31 1.78 -313.72 156.97 116.71
2015-12-31 2.78 -226.43 119.24 112.70
2015-09-30 2.78 -173.00 70.71 107.47
2015-06-30 2.78 -157.95 55.11 107.36
2015-03-31 2.78 -76.58 42.09 93.98
2014-12-31 1.74 -283.23 34.60 80.31
2014-09-30 1.70 -260.77 27.47 66.18
2014-06-30 1.66 -256.66 21.45 47.19
2014-03-31 1.62 -303.61 16.39 37.40
2013-12-31 1.62 -67.79 13.13 27.94
2013-09-30 1.62 -86.24 10.59 23.14
2013-06-30 1.74 -60.69 8.46 18.07
2013-03-31 2.09 -53.05 6.51 17.96
2012-12-31 2.45 -46.27 5.18 16.18
2012-09-30 2.80 -19.85 4.03 15.56
2012-06-30 2.92 -17.25 4.19 14.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intercept Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intercept Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intercept Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intercept Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

I4P Health

 How is Intercept Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intercept Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intercept Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intercept Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Intercept Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intercept Pharmaceuticals Company Filings, last reported 3 months ago.

DB:I4P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 19.13 371.25 436.16
2018-09-30 95.81 367.23 489.09
2018-06-30 146.58 363.30 538.34
2018-03-31 -52.28 359.45 326.09
2017-12-31 16.39 355.68 414.92
2017-09-30 111.67 351.98 492.75
2017-06-30 169.70 348.37 550.31
2017-03-31 240.24 344.83 608.01
2016-12-31 314.93 341.36 689.39
2016-09-30 414.94 337.90 779.96
2016-06-30 416.67 0.00 439.49
2016-03-31 488.33 0.00 556.86
2015-12-31 602.15 0.00 628.06
2015-09-30 677.88 0.00 695.71
2015-06-30 722.94 0.00 732.32
2015-03-31 395.92 0.00 401.99
2014-12-31 230.89 0.00 239.72
2014-09-30 261.06 0.00 272.81
2014-06-30 289.94 0.00 299.03
2014-03-31 -153.74 0.00 134.11
2013-12-31 82.41 0.00 144.91
2013-09-30 90.96 0.00 156.75
2013-06-30 116.27 0.00 161.80
2013-03-31 60.80 0.00 104.22
2012-12-31 65.91 0.00 110.27
2012-09-30 15.64 0.00 36.05
2012-06-30 20.00 0.00 39.83
  • Intercept Pharmaceuticals's level of debt (1940.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1940.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intercept Pharmaceuticals has sufficient cash runway for 1.8 years based on current free cash flow.
  • Intercept Pharmaceuticals has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 3.8% each year.
X
Financial health checks
We assess Intercept Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intercept Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

I4P Dividends

 What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intercept Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Intercept Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intercept Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intercept Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:I4P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:I4P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intercept Pharmaceuticals has not reported any payouts.
  • Unable to verify if Intercept Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intercept Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intercept Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intercept Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Intercept Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intercept Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

I4P Management

 What is the CEO of Intercept Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Pruzanski
COMPENSATION $6,154,687
AGE 50
TENURE AS CEO 17.3 years
CEO Bio

Dr. Mark Pruzanski, M.D., founded Intercept Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since 2002. Dr. Pruzanski serves as the President and Chief Executive Officer at MedicinePlanet, Inc. He has over 12 years of experience in life sciences startup management and venture capital, strategy consulting and healthcare policy. He co-founded Kirax Corporation (Alternate Name: Tigris Pharmaceuticals, Inc.) in 2005. He served as a Venture Partner at Apple Tree Partners (ATP), which he founded in 1999, where he worked with several portfolio companies to assist them in financing, strategic positioning and operations. Prior to that, he served at Oak Investment Partners in Connecticut as an Entrepreneur in Residence with a focus on sourcing technology and startup company origination. Dr. Pruzanski serves as a Director at Equillium, Inc. since September 2018. Dr. Pruzanski serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Foundation for Defense of Democracies. Dr. Pruzanski has been a Director of Intercept Pharmaceuticals, Inc. since 2002. He served as a Director of Evelo Biosciences, Inc. until March 16, 2017. He served as a Director of Evelo Therapeutics, Inc. since July 12, 2016 until January 31, 2017. He served as a Director and Observer at Kirax Corporation (Alternate Name: Tigris Pharmaceuticals, Inc.). Dr. Pruzanski is a Canadian Physician and received his M.D. from McMaster University in Ontario, an M.A. degree in International Affairs from the Johns Hopkins School of Advanced International Studies in Bologna, Italy and Washington, DC and a Bachelor's degree from McGill University in Montreal, Quebec.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Intercept Pharmaceuticals management team in years:

2.2
Average Tenure
49.5
Average Age
  • The tenure for the Intercept Pharmaceuticals management team is about average.
Management Team

Mark Pruzanski

TITLE
Founder
COMPENSATION
$6M
AGE
50
TENURE
17.3 yrs

Sandip Kapadia

TITLE
CFO, Treasurer & Principal Accounting Officer
COMPENSATION
$2M
AGE
48
TENURE
2.8 yrs

Jerry Durso

TITLE
Chief Operating Officer
COMPENSATION
$4M
AGE
50
TENURE
2.2 yrs

David Ford

TITLE
Chief Human Resources Officer
COMPENSATION
$2M
AGE
49
TENURE
1.9 yrs

David Shapiro

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
64
TENURE
11.9 yrs

Mark Vignola

TITLE
Executive Director

Ryan Sullivan

TITLE
General Counsel & Secretary
AGE
42
TENURE
1.2 yrs

Chris Weyer

TITLE
Executive Vice President of Research & Development
AGE
48
TENURE
1.4 yrs

Gail Cawkwell

TITLE
Senior Vice President of Medical Affairs
TENURE
1.2 yrs

Lisa Bright

TITLE
President of International
COMPENSATION
$2M
AGE
50
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Intercept Pharmaceuticals board of directors in years:

4.8
Average Tenure
58.5
Average Age
  • The tenure for the Intercept Pharmaceuticals board of directors is about average.
Board of Directors

Paolo Fundaro

TITLE
Chairman of the Board
COMPENSATION
$394K
AGE
44
TENURE
3.5 yrs

Mark Pruzanski

TITLE
Founder
COMPENSATION
$6M
AGE
50
TENURE
17.3 yrs

Glenn Sblendorio

TITLE
Director
COMPENSATION
$385K
AGE
62
TENURE
5.2 yrs

Luca Benatti

TITLE
Director
COMPENSATION
$380K
AGE
57
TENURE
4.8 yrs

Gino Santini

TITLE
Lead Independent Director
COMPENSATION
$390K
AGE
61

Dan Welch

TITLE
Director
COMPENSATION
$383K
AGE
60
TENURE
3.4 yrs

Scott Friedman

TITLE
Member of the Scientific Advisory Board

Massimo Pinzani

TITLE
Member of the Scientific Advisory Board

Aldo Roda

TITLE
Member of the Scientific Advisory Board

Alan Hofmann

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Dec 18 Sell Lisa Bright Individual 03. Dec 18 04. Dec 18 -5,000 €99.72 €-490,657
03. Dec 18 Sell Genextra S.p.A. Company 29. Nov 18 29. Nov 18 -750,000 €92.34 €-69,251,637
30. Nov 18 Sell Christian Weyer Individual 29. Nov 18 29. Nov 18 -1,343 €99.99 €-134,286
07. Sep 18 Sell David Shapiro Individual 05. Sep 18 05. Sep 18 -4,917 €95.95 €-471,789
X
Management checks
We assess Intercept Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intercept Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

I4P News

Simply Wall St News

I4P Company Info

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Details
Name: Intercept Pharmaceuticals, Inc.
I4P
Exchange: DB
Founded: 2002
$2,342,252,523
29,693,876
Website: http://www.interceptpharma.com
Address: Intercept Pharmaceuticals, Inc.
10 Hudson Yards,
37th floor,
New York,
New York, 10001,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ICPT Common Stock Nasdaq Global Select US USD 11. Oct 2012
DB I4P Common Stock Deutsche Boerse AG DE EUR 11. Oct 2012
Number of employees
Current staff
Staff numbers
483
Intercept Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:45
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.